33 results on '"Lalezari, Shadan"'
Search Results
2. Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center
3. The potential role of emicizumab prophylaxis in severe von Willebrand disease
4. Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY 94-9027 for Severe Haemophilia A: A Post Hoc Analysis
5. Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial
6. Management of surgery in hemophilia A patients on emicizumab prophylaxis: Data from a national hemophilia treatment center
7. Four Decades of Carrier Detection and Prenatal Diagnosis in Hemophilia A: Historical Overview, State of the Art and Future Directions
8. Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study
9. sj-docx-1-tah-10.1177_20406207231166779 – Supplemental material for Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ≽40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study
10. Molecular Mechanisms of Skewed X-Chromosome Inactivation in Female Hemophilia Patients—Lessons from Wide Genome Analyses
11. Real World Data of Extended Venous Thromboembolism Prophylaxis with Low Dose Apixaban Following Cancer Associated Thrombosis
12. Safety and efficacy of BAY 94–9027, an extended‐half‐life factor VIII, during minor surgical procedures in patients with severe haemophilia A
13. Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study
14. Women with Hemophilia: Case Series of Reproductive Choices and Review of Literature
15. The Potential Role of Emicizuamb Prophylaxis in Severe Von Willebrand Disease
16. Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027
17. Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection
18. BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years
19. Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study
20. BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results
21. Allele-specific replication associated with aneuploidy in blood cells of patients with hematologic malignancies
22. Decrease in Overall and Joint Bleeding Rates with Extended-Interval Dosing: > 4 Years of Bay 94-9027 Prophylaxis in the Protect VIII Extension
23. Extended Interval Prophylaxis with Bay 94-9027 for > 4 Years Leads to Median Spontaneous Annualized Bleeding Rates < 1 in the Protect VIII Extension
24. Neonatal circumcision in patients with haemophilia is safe – a single centre experience
25. Rationale for Investigator-Assigned Prophylaxis Dosing Frequency in the Leopold I Study
26. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study.
27. Efficacy, PK and Safety Results of a Phase I/II Clinical Trial of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Haemophilia B (PROLONG - 9FP)
28. Impact of ethnic background and methylenetetrahydrofolate reductase genotype on age at onset of coronary artery disease among women in Israel
29. Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hocanalysis from the PROTECT VIII study
30. Acquired Hemophilia A in a Patient with Non-Small Cell Lung Carcinoma: A Rare Paraneoplastic Phenomenon.
31. Methylenetetrahydrofolate Reductase Genotypes and Early-Onset Coronary Artery Disease
32. The Impact of Emicizumab Prophylaxis on Hospitalizations and Emergency Department Visits Among Hemophilia A Patients Is Age Related.
33. Acquired Hemophilia A in a Patient with Non-Small Cell Lung Carcinoma: A Rare Paraneoplastic Phenomenon.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.